ASUS is ready to debut two new big-screen gaming laptops, the Zephyrus M16 and S17.
Stock futures sank Tuesday morning, with the Nasdaq looking to add to losses as technology stocks came under increasing selling pressure as inflation concerns rose.
(Bloomberg) -- Chinese debt is back in favor with overseas investors.After the nation’s government bonds suffered their first outflow in two years in March, foreigners added 52 billion yuan ($8.1 billion) to their holdings in April, bringing the total to a record 2.1 trillion yuan, data compiled by ChinaBond show.In a game-changing shift -- compared by some to the birth of the euro -- yuan-denominated debt has emerged as a refuge during this year’s global bond rout. Investors looking for diversification have piled in, seeking its relatively high yields and low correlation to other markets. While that partially reversed in March, as rising U.S. yields dimmed Chinese bonds’ appeal, the quick turnaround has underscored the resilience of demand and China’s growing clout since opening its fixed-income market.“The underlying case for Chinese bonds is still very, very strong,” said Pramol Dhawan, head of emerging markets portfolio management at Pacific Investment Management Company LLC. “Because of its low correlation to global rates, its high nominal yields and high real yields form a very important part of portfolio construction.”Foreign investment in China’s interbank fixed-income market, as compiled by ChinaBond, rose 65 billion yuan in April to an all-time high of 3.2 trillion yuan, the data showed. Those holdings more than doubled over the past two years as Chinese bonds were included in global benchmarks compiled by Bloomberg Barclays and JPMorgan Chase & Co. Still, foreign investors only account for 4.3% of the total debt in China’s interbank market.“We are increasing our exposure to the Chinese bonds,” said Kheng Siang Ng, Asia Pacific head of fixed income at State Street Global Advisors. “It’s hard for the markets to ignore.”Read More: China’s Bonds Only One to Gain Among Biggest Markets in RoutEven as foreign investors returned, the April numbers suggest the momentum of inflows has slowed from the breathtaking pace earlier this year. Last month’s inflow was less than half the amount seen in January.The yield premium of China’s benchmark 10-year bond over Treasuries narrowed by around 1 percentage point to about 154 basis points from a record in November. On top of that, FTSE Russell said in March that it will take three years to add Chinese debt into its global index, instead of the 12 months initially envisioned. That disappointed some investors who expected a faster inclusion.Defensive BuyersNick Maroutsos, head of global bonds at Janus Henderson Investors, is among those who aren’t yet ready to buy Chinese bonds.“We get asked this a lot, and my answer to whether we own or will own Chinese bonds is, ‘Not right now,’” said Maroutsos, whose firm managed more than $414 billion as of March.“Ultimately, we are defensive buyers, and I have a hard time looking at emerging markets as a safe haven for investors,” he said. “Chinese government bonds aren’t going to protect you and won’t behave in a manner similar to Treasuries.”China’s bonds have been dancing to their own tune, in part because they are less owned by foreign investors, and China’s independent economic and policy cycles set them apart from the rest of the world.Over the past 10 years, their correlation with the U.S. Treasuries was less than 0.2, according to a Bloomberg analysis. Yields on 10-year Chinese bonds were little changed this year, while equivalent Treasury yields surged 69 basis points.Read More: Carry Trades in China, Korea Are Best in Low-Yield Covid EraWhile the yield spread has narrowed, at 3.1%, China’s 10-year yield is almost double that of Treasuries. Even if U.S. yields rise further, Chinese bonds remain appealing because of their low correlation to global markets, which helps investors lower volatility in their portfolio, said Lucy Qiu, a strategist at UBS Global Wealth Management.“Investors still need to look for uncorrelated sources of returns, as negative bond-equity correlations may be challenged during a rapid rise in yield,” Qiu said.(Updates with performance data in third-from-last paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Dublin, May 11, 2021 (GLOBE NEWSWIRE) -- ResearchAndMarkets.compublished a new article on the petroleum industry "Oil Prices Rise Again" Oil prices moved higher after the Energy Information Administration reported a crude oil inventory draw of 8 million barrels for the week to April 30. The oil inventory figure compared with a weekly draw of 7.688 million barrels estimated by the American Petroleum Institute a day earlier, and with a moderate build of 100,000 barrels that the EIA reported for the previous week. Analysts had expected the EIA to report a crude oil inventory decline of 2.19 million barrels for the period. In gasoline, the authority estimated a minor stock build of 700,000 barrels for the last week of April. This compared with another modest build of 100,000 barrels for the previous week. Production last week averaged 9.1 million bpd, which compared with 9.6 million bpd during the previous week. The article on ResearchAndMarkets.com contains a selection of reports on petroleum such as: Asia Oil & Gas MonitorOil & Gas Industry in India: Insights into Human Capital & Locations 2020Oil & Gas Automation & Control Systems Market by Technology, by Application - Global Opportunity Analysis and Industry Forecast, 2020 - 2030 To see the full article and a list of related reports on the market, visit "Oil Prices Rise Again" About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Model B today announced the addition of award-winning ad executive Todd Silverstein as President.
The "Methanol Market - Growth, Trends, and Forecast (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
Walmart Inc. (NYSE: WMT) today announced it will hold a live conference call with the Investment Community at 7 a.m. CDT on Tuesday, May 18, 2021, to discuss the company’s first quarter earnings results for fiscal year 2022. Doug McMillon, president and chief executive officer, and Brett Biggs, executive vice president and chief financial officer, will host the call to discuss the results and answer questions.
Calix has launched the world's first Wi-Fi system that can accommodate deployments from 1-10 Gbps and offer an unprecedented 10-year life span
SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Peloton Interactive, Inc. (NASDAQ: PTON) shares. Investors, who purchased shares of Peloton Interactive, Inc. (NASDAQ: PTON) prior to September 2020 and continue to hold any of their NASDAQ: PTON shares, have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554. On April 29, 2021, a lawsuit was filed against Peloton Interactive, Inc. over alleged violations of securities laws. The plaintiff alleged that the defendants made false and/or misleading statements and/or failed to disclose that in addition to the tragic death of a child, Peloton’s Tread+ had caused a serious safety threat to children and pets as there were multiple incidents of injury to both, that safety was not a priority to Peloton as defendants were aware of serious injuries and death resulting from the Tread+ yet did not recall or suggest a halt of the use of the Tread+, that as a result of the safety concerns, the U.S. Consumer Product Safety Commission (“CPSC”) declared the Tread+ posed a serious risk to public health and safety resulting in its urgent recommendation for consumers with small children to cease using the Tread+; (4) the CPSC also found a safety threat to Tread+ users if they lost their balance, and that as a result of the foregoing, defendants’ statements about Peloton’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. Those who purchased Peloton Interactive, Inc. (NASDAQ: PTON) shares should contact the Shareholders Foundation, Inc. CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 firstname.lastname@example.org 3111 Camino Del Rio North Suite 423 San Diego, CA 92108 The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
Annual inflation in Brazil rose to 6.8% in April, the highest since 2016, official figures showed on Tuesday, driven by higher healthcare and pharmaceutical goods prices as well as a rise in food and drink costs. The annual rate of consumer inflation rose to 6.8% from 6.1% in March, statistics agency IBGE said, exactly in line with the median forecast in a Reuters poll of economists and the highest since November 2016. Monthly inflation slowed to 0.3% in April from 0.9% in March, IBGE said, again exactly as economists in the Reuters poll had forecast.
- Intracochlear delivery of a dual AAVAnc80 vector encoding human otoferlin results in full-length protein expression in inner hair cells of non-human primates and in durable protein expression sufficient for sustained restoration of auditory function in Otof knockout mice - Multiple analyses demonstrate in vitro transduction with dual AK-OTOF vector results in full-length otoferlin expression, with no detection of truncated proteins - Long-term, local expression of anti-VEGF protein is robust and well tolerated following intracochlear administration of AK-antiVEGF in non-human primates - Akouos continues to progress towards planned IND submissions for AK-OTOF in the first half of 2022 and for AK-antiVEGF in 2022 BOSTON, May 11, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today presented nonclinical data supporting the future clinical development of both AK-OTOF, a gene therapy intended for the treatment of otoferlin gene (OTOF)-mediated hearing loss, and AK-antiVEGF, a gene therapy intended for the treatment of vestibular schwannoma, in three digital presentation sessions at the virtual American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting. “We are excited to share new data that highlight the potential of genetic medicines for inner ear conditions with the broader gene therapy community,” said Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos. “Inner ear conditions represent one of the largest areas of unmet need in medicine today, and one of the challenges in this area is the ability to efficiently address the broad range of conditions that collectively affect hundreds of millions of individuals worldwide. The nonclinical data presented today for the AK-OTOF and AK-antiVEGF programs demonstrate how we are leveraging our genetic medicines platform and multiple AAV-mediated modalities, including gene transfer and therapeutic protein expression, to begin to address that challenge.” “Nonclinical data presented at ASGCT for AK-OTOF continue to support the potential to restore physiologic hearing and provide long-lasting benefit to individuals with OTOF-mediated hearing loss. In Otof knockout mice, AK-OTOF administration results in durable expression of human otoferlin protein sufficient for sustained restoration of auditory function. In addition, data presented indicate that expression of exogenous secreted protein at or above reported biologically active levels, driven by a ubiquitous promoter, is well tolerated in non-human primates following administration of AK-antiVEGF. These IND-enabling nonclinical studies are promising and support future clinical development. Our team continues to work towards submission of INDs for AK-OTOF and AK-antiVEGF expected in 2022,” said Greg Robinson, Ph.D., chief scientific officer of Akouos. In Vitro and In Vivo Analyses of Dual Vector Otoferlin Expression to Support the Clinical Development of AK-OTOF (AAVAnc80-hOTOF Vector) Presenting Author: Eva Andres-Mateos Abstract Number: 355 Otoferlin plays a critical role in exocytosis of synaptic vesicles at the inner hair cell synapse, and mutations in OTOF, the gene encoding otoferlin, are associated with autosomal recessive sensorineural hearing loss. AK-OTOF is designed to deliver normal OTOF by utilizing a dual vector approach, which encodes the 5’ and the 3’ components of OTOF. Multiple analyses demonstrate in vitro transduction with dual AK-OTOF vector results in full-length human otoferlin (RNA and protein), with no detection of truncated proteins from either AK-OTOF or its component vectors (5’hOTOF and 3’hOTOF). A one-to-one ratio of the AK-OTOF component vectors appears to be optimal for efficient reconstitution of full-length human otoferlin. In cynomolgus macaques, full-length human otoferlin protein expression is detected in inner hair cells of non-human primate (NHP) cochleae by both immunohistochemistry and immunodetection one month following intracochlear administration of AAVAnc80-FLAG.hOTOF. The digital presentation is located at https://akouos.com/gene-therapy-resources/. Durable Recovery of Auditory Function Following Intracochlear Delivery of AK-OTOF (AAVAnc80-hOTOF Vector) in a Translationally Relevant Mouse Model of Otoferlin Gene (OTOF)-Mediated Hearing Loss Presenting Author: Ann Hickox Abstract Number: 569 Otoferlin gene (OTOF)-mediated hearing loss is caused by mutations in the OTOF gene and is typically characterized by a congenital, Severe to Profound sensorineural hearing loss. The physiologic deficiency resulting from OTOF mutations is localized; specifically, synaptic transmission between the inner hair cell and the auditory nerve is affected, as measured by an absent or abnormal auditory brain stem response (ABR). Gene therapy for OTOF-mediated hearing loss is expected to confer the greatest benefit when cochlear integrity is preserved, as represented by present otoacoustic emissions (OAEs). Individuals with OTOF-mediated hearing loss typically experience a decline in cochlear integrity within the first decade of life, indicated by initially present, then absent, OAEs. In an Otof knockout mouse model that recapitulates the human phenotype, administration of AK-OTOF, an adeno-associated viral gene therapy vector encoding human otoferlin under the control of a ubiquitous promoter, results in durable restoration of auditory function, as measured by ABRs, and may preserve OAEs. The digital presentation is located at https://akouos.com/gene-therapy-resources/. Demonstration of Tolerability of a Novel Delivery Approach and Secreted Protein Expression Following Intracochlear Delivery of AK-antiVEGF (AAVAnc80-antiVEGF Vector) in Non-Human Primates Presenting Author: John Connelly Abstract Number: 358 Data published from previous clinical trials show that systemic VEGF inhibitor therapy can reduce vestibular schwannoma (VS) tumor volume and improve hearing in some participants with mutations in the NF2 gene. However, toxicity limits the potential of this systemic delivery approach from being a viable treatment option for vestibular schwannoma. The exposure and tolerability of local expression of anti-VEGF protein following bilateral, intracochlear administration of AK-antiVEGF was evaluated through analyses of protein levels, as well as physiologic and histologic evaluations, in NHPs. Long-term, local expression of anti-VEGF protein, driven by a ubiquitous promoter, is robust and well tolerated in NHPs following intracochlear administration of AK-antiVEGF. Computational modelling supports the potential for diffusion of anti-VEGF protein at or above reported biologically active levels to the site of the VS tumor. The digital presentation is located at https://akouos.com/gene-therapy-resources/. About Akouos Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy. Cautionary Note Regarding Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the initiation, plans, and timing of our future clinical trials and our research and development programs, the timing of our IND submissions for AK-OTOF and AK-antiVEGF, our expectations regarding our manufacturing capabilities and timelines, and the period over which we believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: our limited operating history; uncertainties inherent in the development of product candidates, including the initiation and completion of nonclinical studies and clinical trials; whether results from nonclinical studies will be predictive of results or success of clinical trials; the timing of and our ability to submit applications for, and obtain and maintain regulatory approvals for, our product candidates; our expectations regarding our regulatory strategy; our ability to fund our operating expenses and capital expenditure requirements with our cash, cash equivalents, and marketable securities; the potential advantages of our product candidates; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential addressable patient population for our product candidates; our commercialization, marketing, and manufacturing capabilities and strategy; our ability to obtain and maintain intellectual property protection for our product candidates; our ability to identify additional products, product candidates, or technologies with significant commercial potential that are consistent with our commercial objectives; the impact of government laws and regulations; risks related to competitive programs; the potential that our internal manufacturing capabilities and/or external manufacturing supply may experience delays; the impact of the COVID-19 pandemic on our business, results of operations, and financial condition; our ability to maintain and establish collaborations or obtain additional funding; and other factors discussed in the “Risk Factors” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission, and in other filings that the Company makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Contacts Media:Katie Engleman, 1ABkatie@1abmedia.com Investors:Courtney Turiano, Stern Investor Relations Courtney.Turiano@sternir.com
Dublin, May 11, 2021 (GLOBE NEWSWIRE) -- The "Injection Molding: Global Markets and Technologies 2020-2025" report has been added to ResearchAndMarkets.com's offering. The global market for plastic injection molding should increase from $121.40 billion in 2020 to $157.70 billion by 2025, at a compound annual growth rate (CAGR) of 5.4% during the period of 2020-2025. Injection molding of plastics is continuing its dominance within the processing of polymers to render products for everyday use, including kitchenware, toys and packaging, among other end-use industries. Amid the recovery of major world economies, in the post-COVID phase, during early 2021, molders are gradually moving towards the attainment of pre-COVID performance standards. However, demand for plastic resins is soaring, with massive demand in the global market. In the current phase, partnership with trusted experts is likely to promote growth. Market players are increasingly investing in the acquisition of new machinery and equipment and focusing on hiring skilled workers to cater to growing demand, especially in the medical sector. Rapid globalization, growing consumerism and rapid technological advancement have brought a plethora of opportunities for the market players, globally. The industry is consistently engaged in conducting extensive (R&D) activities to develop innovative and efficient materials. Moreover, a rise in realization, achievement of economies of scale and operational efficiency will continue to aid market players in achieving desired performance targets. Report Scope: This study encompasses technologies, applications and materials regarding injection molding. The report analyzes the major types of thermoplastic resins used to produce molded products. These products cater to demand arising from various end-use industries. Machines and equipment are discussed, entailing the qualitative aspect of it. Trends in demand are reviewed and impact on the overall market growth are assessed. Market drivers within each end-use industry are identified. Thermoplastic resin injection molding is analyzed in detail. Technological issues and trends are reviewed and other influential factors (economic conditions, COVID impact and standards) are discussed. Because this is a global study, the research analyzes domestic and international technological issues and economic considerations. Revenue forecasts from 2019-2025 are given for each major type of thermoplastic grade, end user and regional market. This updated report includes the impact of COVID-19 on the end-user base, which can be seen in the global and regional market analysis. Key Topics Covered: Chapter 1 Introduction Study Goals and ObjectivesReasons for Doing This StudyScope of ReportInformation SourcesMethodologyGeographic BreakdownAnalyst's CredentialsCustom ResearchRelated Reports Chapter 2 Summary and Highlights Chapter 3 Market and Technology Background History of Plastic Injection MoldingThe Beginning PhaseIndustry: Post WWIIHendry and Plastic Injection MoldingCurrent ScenarioDefinition of Plastic Injection MoldingMarket DynamicsKey DriversKey ChallengesKey OpportunitiesStrategic Innovations after 2018Plastic Molding TechniquesPlastic Molding ProcessesBlow MoldingCompression MoldingFilm Insert MoldingGas Assist MoldingReactive Injection Molding (RIM)Two-Shot Injection MoldingMicro Injection MoldingRotational MoldingStructural Foam MoldingThermoformingInjection Molding vs. Other Plastic Molding ProcessesKey ConsiderationsThermoplastic PolymersPolyethylene (PE)Polypropylene (PP)Polyvinyl Chloride (PVC)NylonsAcrylonitrile Butadiene Styrene (ABS)Polystyrene (PS)Other Injection Molding Thermoplastic Polymers UsedThe Plastic Injection Molding ProcessThe Injection Molding CycleThe MoldRunner SystemPreparing the MoldProcess VariationsInjection Molding ConsiderationsWall Section ConsiderationsRecent Developments/InnovationsMicro-MoldingTwo-Shot Micro-MoldingImpact of COVID-19 on the Market for Plastic Injection Molding Chapter 4 Plastic Injection Molding Machinery and Systems Injection Molding MachineryHydraulic Injection Molding MachinesElectric Injection Molding MachinesHybrid Injection Molding MachinesType of Injection Machine by ArrangementHorizontal Injection Molding MachinesVertical Injection Molding MachinesHybrid Injection Molding MachinesTwo-Color Injection Molding MachinesMulti-Material Injection Molding MachinesRotary Injection Molding MachinesLow Foam Injection Molding MachinesSandwich Injection MachinesGas-Assisted Injection Molding MachinesWater Injection Technology/Water-Assisted Injection Molding MachinesMicro-Injection Molding Machines Chapter 5 Market Breakdown by Type of Polymer Polypropylene PlasticsABSPolystyreneHDPEPolycarbonatePolyamide (Nylon)PolyurethaneOther Plastics Chapter 6 Market Breakdown by End Use Packaging and Product HousingPower Tool HousingElectrical SwitchesBottle Lids/ClosuresPlastic Bins and CratesReusable ContainersWhite Goods Housing and PackagingMedical Devices and PharmaceuticalsAutomotiveTelecommunicationsIndustrial and Business MachinesAgricultureInfrastructureOther End Uses Chapter 7 Market Breakdown by Region Asia-PacificNorth AmericaEuropeRest of the World Chapter 8 New Developments Trends over Time Chapter 9 Market Opportunities Emerging Trends in Plastic Injection MoldingPlastic Injection Molding Process TrendsEnd-Use InnovationsPrototyping Chapter 10 Company Profiles Leading Plastic Injection Molding Machine ManufacturersAbsolute Haitian Corp.Bay Plastics MachineryDavis-Standard LlcDri-Air Industries Inc.Engel Austria GmbhGammaflux Controls Inc.Graham Engineering Corp.Husky Injection Molding Systems Ltd.Industrial Heater Corp.Kautex Machines Inc.Maguire Products Inc.Maruka Usa Inc.Master Molded Products Corp.Milacron LlcNegri Bossi North AmericaNissei Plastic Industrial Co., Ltd.Nordson Polymer Processing SystemsNovatec, Inc.Parkinson Technologies Inc.Sumitomo (Shi) DemagUbe Machinery Inc.Universal Dynamics Inc.Wittmann Battenfeld Inc.Yudo Co., Ltd.Yushin America Inc.Leading Plastic Injection Molding Polymer And End-User Goods ManufacturersAdvantech Plastics LlcAptargroup Inc.BASF SEBecton Dickinson And Co.Berry Global Group Inc.C&J IndustriesDenroy Plastics Ltd.Dow Chemicals Co., Ltd.DSMDupontEastman Chemical Co.Exxonmobil Corp.Ht PlasticsHuntsman Corp.IcomoldIneos GroupLacks Enterprises Inc.Lyondellbasell Industries N.V.Magna International Inc.Midstate Mold & EngineeringMSI Mold BuildersNew Berlin Plastics Inc.Newell RubbermaidNypro Inc.Rutland Plastics Ltd.SabicStack Plastics Inc.Toray Industries, Inc.Zeiger Industries For more information about this report visit https://www.researchandmarkets.com/r/vcdszw CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Ultium Cells LLC, a joint venture between General Motors and LG Chem, has been steadily building up its battery cell manufacturing capacity in the U.S. since the venture was first announced in December 2019. Instead of throwing it away, Ultium is sending it to a recycler. The venture has executed an agreement with Canadian company Li-Cycle to recycle critical materials from the scrap produced from Ultium’s manufacturing processes from its Lordstown plant, starting later in 2020.
Labour leader Keir Starmer’s woes continue to mount after his closest parliamentary aide suddenly resigned. Carolyn Harris, who had served as Sir Keir’s Starmer’s parliamentary private secretary since he became leader last year, has left the role. It marks the continuation of a torrid weekend for the Labour leader, who carried out a strained reshuffle of his top team after the party’s defeat in the Hartlepool by-election last week.
Elliott Investment Management L.P. ("Elliott") announces today that funds it advises have entered into a definitive agreement to acquire the assets and business operations of Paper Source Inc.
(Bloomberg) -- The world’s largest money managers may be underestimating the durability of inflation after a record wave of money printing to combat the Covid-19 pandemic, according to veteran investor Mark Mobius.This will pose a particular problem in the U.S., where a rising inflation rate will weigh on the global reserve currency, said Mobius, who set up Mobius Capital Partners after three decades at Franklin Templeton Investments. At the same time, the quickening price growth is likely to support a rally in raw materials, even as the Bloomberg Commodity Index already hovers near its highest since July 2015, he said.READ MORE: Inflation Debate Hits Emerging Markets as Pimco Stands Firm Such a backdrop favors emerging markets, which will grow faster than their developed-nation peers in the years ahead, Mobius said. Chinese and Indian equities, recently beaten down by a rout in technology shares as well as the latest Covid-19 crisis, look particularly attractive, he said on Bloomberg TV. Yet he voiced caution about fully rotating into value stocks.“With continuing low interest rates, normal parameters like P/E ratios aren’t a good guide for where you should be,” Mobius said from Cairo. “The numbers to look at are return on capital and dividend yield. But I think you have to have a combination of value and growth.”His concerns on inflation were underscored Tuesday by new data showing a surge in Chinese factory-gate prices. Even so, central bankers from the U.S. and elsewhere maintain that price gains are temporary. In China, the world’s largest exporter, policy makers insist that price growth remains mostly under control. Still, officials have pledged to strengthen controls on the raw-materials market to limit costs to companies.(Updates with data on Chinese factory prices in fifth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Refugees and students would be among those exempted from proposal
FOOTHILL RANCH, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Kaiser Aluminum Corporation (Nasdaq:KALU) announced today that it plans to offer $500.0 million aggregate principal amount of senior notes due 2031 (the “notes”) in a private transaction that is exempt from the registration requirements of the Securities Act of 1933 (the “Act”). The notes will be guaranteed by each of Kaiser Aluminum’s existing and future domestic subsidiaries that is a borrower or guarantor under Kaiser Aluminum’s revolving credit facility. Kaiser Aluminum intends to use the net proceeds from the offering of the notes to redeem all $350 million aggregate principal amount of Kaiser Aluminum’s existing 6.500% senior notes due 2025 (the “2025 notes”), and for general corporate purposes, which may include, among other things, capital spending and acquisitions. The consummation of the offering of notes is subject to market conditions. On May 11, 2021, Kaiser Aluminum provided conditional notice of its intent to redeem the 2025 notes on May 21, 2021. This press release does not constitute a notice of redemption with respect to the 2025 notes. The notes and the related guarantees have not been and will not be registered under the Act or the securities laws of any other place and may not be offered or sold in the United States absent registration or an applicable exemption therefrom. The notes will be offered only to persons reasonably believed to be qualified institutional buyers under Rule 144A and to non-U.S. persons outside the United States under Regulation S. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities, and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. This notice is being issued pursuant to and in accordance with Rule 135c under the Act. Forward-Looking Statements This press release contains statements which constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the beliefs and assumptions of management based on information available to it at the time such statements are made. Kaiser Aluminum cautions that any forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of various factors. These factors include: (a) the effectiveness of management's strategies and decisions, including capital spending strategies and decisions; (b) general economic and business conditions, including the impact of the global outbreak of Coronavirus Disease 2019 and governmental and other actions taken in response, cyclicality, reshoring and other conditions that impact demand drivers in the aerospace/high strength, automotive, general engineering, packaging and other end markets Kaiser Aluminum serves; (c) Kaiser Aluminum’s ability to participate in mature and anticipated new automotive programs expected to launch in the future and successfully launch new automotive programs; (d) changes or shifts in defense spending due to competing national priorities; (e) pricing, market conditions and Kaiser Aluminum’s ability to effectively flex costs in response to changing economic conditions; (f) developments in technology; (g) the impact of Kaiser Aluminum's future earnings, cash flows, financial condition, capital requirements and other factors on its financial strength and flexibility; (h) new or modified statutory or regulatory requirements; (i) the successful integration of the acquired operations and technologies that continue to drive innovative solutions and further advance its capabilities, (j) the completion of purchase price allocation and other adjustments in connection with the Warrick acquisition, and (k) other risk factors summarized in Kaiser Aluminum's reports filed with the Securities and Exchange Commission, including Kaiser Aluminum's Form 10-K for the year ended December 31, 2020 and Form 10-Q for the quarter ended March 31, 2021. Kaiser Aluminum undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in Kaiser Aluminum’s expectations. Investor Relations and Public Relations Contact: Melinda C. EllsworthKaiser Aluminum Corporation(949) 614-1757
This pandemic-induced boom took the U.S. cannabis industry to great heights. Among the stocks affected was Illinois-based Green Thumb Industries (OTC: GTBIF), whose exceptional performance last year makes it my top cannabis pick right now. Illinois legalized recreational cannabis on Jan. 1, 2020, and saw record-breaking sales throughout the year -- total legal marijuana revenue hit the $1 billion mark, with $669 million of that coming from recreational pot.